Previous close | 0.3500 |
Open | 0.3000 |
Bid | 0.0000 |
Ask | 0.4500 |
Strike | 1.00 |
Expiry date | 2024-05-17 |
Day's range | 0.2500 - 0.3500 |
Contract range | N/A |
Volume | |
Open interest | 14 |
Detailed Analysis of Financial Performance and Future Outlook
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and multiple ascending dose (MAD) cohorts of the randomized, double-blind, placebo-controlled
Key Insights Institutions' substantial holdings in Allakos implies that they have significant influence over the...